1. Home
  2. SPT vs GLSI Comparison

SPT vs GLSI Comparison

Compare SPT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$5.54

Market Cap

327.6M

Sector

Technology

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$21.49

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
GLSI
Founded
2010
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.6M
372.0M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
SPT
GLSI
Price
$5.54
$21.49
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$12.38
$50.00
AVG Volume (30 Days)
1.7M
137.2K
Earning Date
05-07-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
N/A
EPS
N/A
N/A
Revenue
$457,547,000.00
N/A
Revenue This Year
$9.03
N/A
Revenue Next Year
$8.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.72
N/A
52 Week Low
$5.39
$7.78
52 Week High
$24.74
$34.10

Technical Indicators

Market Signals
Indicator
SPT
GLSI
Relative Strength Index (RSI) 34.76 37.89
Support Level N/A $9.50
Resistance Level $7.39 $30.02
Average True Range (ATR) 0.31 2.18
MACD 0.06 -0.55
Stochastic Oscillator 15.75 7.00

Price Performance

Historical Comparison
SPT
GLSI

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: